Michael May

Vorstandsvorsitzender bei

Centre For Commercialization of Regenerative Medicine

58 Jahre

79 Beziehungen

Health Technology

Health Services

Consumer Services

Profil

Michael H.
May founded Rimon Therapeutics Ltd., where he worked as Chief Operating Officer from 2006 to 2010.
Dr. May also currently works at Centre For Commercialization of Regenerative Medicine, as President, Chief Executive Officer & Director, CCRM Enterprises Inc, as Chief Executive Officer, ExCellThera, Inc., as Chairman, ExCellThera Ltd., as Chairman, Omniabio, Inc., as Chairman, 20, as Director, Toronto Innovation Acceleration Partners, as Director, The Centre for the Commercialization of Antibodies & Biologics, as Director, and Foundation For Cell & Gene Medicine, as Director.
Dr. May also formerly worked at Alliance for Regenerative Medicine, as Director, The Ontario Institute For Regenerative Medicine, as Director, and AgeX Therapeutics, Inc., as Independent Director from 2019 to 2023.
Dr. May received his doctorate degree in 1998 from the University of Toronto.

Aktive Positionen von Michael May

Unternehmen	Position	Beginn
Toronto Innovation Acceleration Partners Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Operates as a commercialization agent	Direktor/Vorstandsmitglied	-
Centre For Commercialization of Regenerative Medicine Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Provides regenerative medicine-based technologies and cell and gene therapy	Vorstandsvorsitzender	-
20/20 Vision Centers, Inc. 20/20 Vision Centers, Inc. Medical/Nursing ServicesHealth Services Provides lasik surgery services	Direktor/Vorstandsmitglied	-
ExCellThera Ltd.	Vorsitzender	-
ExCellThera, Inc. ExCellThera, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company which engages in cell expansion and bioengineering activities	Vorsitzender	-
CCRM Enterprises Inc	Vorstandsvorsitzender	-
Omniabio, Inc. Omniabio, Inc. BiotechnologyHealth Technology Develops stem cell and gene therapies	Vorsitzender	-
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine.	Direktor/Vorstandsmitglied	-
The Centre for the Commercialization of Antibodies & Biologics The Centre for the Commercialization of Antibodies & Biologics Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Michael May

Ehemalige bekannte Positionen von Michael May

Unternehmen	Position	Ende
░░░░ ░░░░░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░░░░ ░░░ ░░░░░░░░░░░░ ░░░░░░░░	░░░░░░░░░░░░░░░░░░░░░░░░░░	-
░░░ ░░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░░░░░░░ ░░░░░░░░	░░░░░░░░░░░░░░░░░░░░░░░░░░	-

Sehen Sie sich die Erfahrung von Michael May im Detail an

Ausbildung von Michael May

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Michael May im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	14
20/20 Vision Centers, Inc. 20/20 Vision Centers, Inc. Medical/Nursing ServicesHealth Services Provides lasik surgery services	Health Services
University of Toronto University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Rimon Therapeutics Ltd. Rimon Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures medical polymers which helps to treat chronic wounds	Health Technology
Toronto Innovation Acceleration Partners Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Operates as a commercialization agent	Health Technology
Alliance for Regenerative Medicine Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine	Health Services
Centre For Commercialization of Regenerative Medicine Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Provides regenerative medicine-based technologies and cell and gene therapy	Health Technology
The Ontario Institute For Regenerative Medicine The Ontario Institute For Regenerative Medicine Miscellaneous Commercial ServicesCommercial Services Operates as stem cell and regenerative medicine research company	Commercial Services
AgeX Therapeutics, Inc. AgeX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics	Health Technology
ExCellThera, Inc. ExCellThera, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company which engages in cell expansion and bioengineering activities	Health Technology
ExCellThera Ltd.
The Centre for the Commercialization of Antibodies & Biologics The Centre for the Commercialization of Antibodies & Biologics Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products	Health Technology
CCRM Enterprises Inc
Omniabio, Inc. Omniabio, Inc. BiotechnologyHealth Technology Develops stem cell and gene therapies	Health Technology
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine.